Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5679016 | European Journal of Internal Medicine | 2017 | 9 Pages |
Abstract
Evolocumab administered at 140Â mg Q2W was more effective than the 420Â mg Q4W dosage at lowering lipid concentrations, especially in patients who concomitantly received stable statin therapy.
Keywords
EvolocumabVLDL-CHoFHRCTsCHDHDL-CPCSK9LDL-CLDLRALTQ2WQ4WTEAERandomized controlled trialsASTAspartate aminotransferaseAlanine aminotransferasestandard deviationcoronary heart diseasecardiovascular diseaseTriglyceridesRelative riskCVDnon-HDL-Cconfidence intervalMeta-analysismean differenceHomozygous familial hypercholesterolemiaProprotein convertase subtilisin/kexin type 9total cholesterolhigh density lipoprotein cholesterolVery low density lipoprotein cholesterolNon-high-density lipoprotein cholesterollow density lipoprotein cholesterollow density lipoprotein receptor
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Xiao-Xiao He, Rong Zhang, Pei-Yuan Zuo, Yu-Wei Liu, Xiang-Nan Zha, Sheng-Shuai Shan, Cheng-Yun Liu,